Cimeio Therapeutics announced that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases with high unmet need.
“This partnership represents a significant step forward for our company and mission.”
The partnership combines Cimeio’s proprietary Shielded-Cell & Immunotherapy Pairs (SCIP) platform with Kyowa Kirin’s expertise in cellular therapies and underscores both companies’ commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients. Under the terms of the agreement, Cimeio is eligible to receive an upfront payment and two years of research funding. Upon Kyowa Kirin’s exercise of a commercial license option, Cimeio will be eligible for development and commercial milestones as well as royalties on sales of potential products arising from the partnership. Further terms are not disclosed.
HealthTech Insights: Hyundai Supports UCI Health with Diabetes Donation
Cimeio’s SCIP platform is based on the development of novel immunotherapies enabled by epitope-shielded cells. These cells contain modified variants of naturally occurring cell surface proteins that maintain their function but are resistant to depletion by the paired immunotherapy. These shielded cells enable the development of powerful therapeutics for previously undruggable targets, targeted conditioning for HSC transplant, and immune system reset amongst other applications.
“We are thrilled to collaborate with Kyowa Kirin, a company with a rich history of investing in innovative technologies that have the potential to significantly improve outcomes for patients with serious conditions,” said Dr. Stefanie Urlinger, CSO of Cimeio. “This partnership represents a significant step forward for our company and mission.”
HealthTech Insights: ESYA Labs Partners with Alamar Biosciences to Advance Biomarker Detection and Diagnostics for Neurological Diseases
“Kyowa Kirin and Cimeio share the vision for the potential of therapeutics enabled by epitope-shielded cells,” said Yoshifumi Torii, Ph.D., Executive Officer, Senior Vice President, Head of Research Division of Kyowa Kirin. “With this partnership we believe we can develop a safe and effective therapy for diseases that in the past have been incredibly difficult to treat, and we’re looking forward to working with the talented team at Cimeio.”
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – Businesswire
